- Home
- ATXS
as 11-15-2024 4:00pm EST
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 669.8M | IPO Year: | 2015 |
| Target Price: | $25.60 | AVG Volume (30 days): | 219.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.26 - $16.90 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Astria Therapeutics Inc. News
ATXS Breaking Stock News: Dive into ATXS Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Business Wire
4 days ago
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
Business Wire
13 days ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
18 days ago
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
Business Wire
a month ago
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
Simply Wall St.
a month ago
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth
Business Wire
a month ago
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
Business Wire
a month ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare ATXS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATXS Astria Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.